Analysis of U-47700, a novel synthetic opioid, in human urine by LC-MS-MS and LC-QToF

Steven W. Fleming, Justin C. Cooley, Leonard Johnson, C. Clinton Frazee, Kristina Domanski, Kurt Kleinschmidt, Uttam Garg

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The illicit drug market has rapidly evolved from synthetic cannabinoids to cathinone derivatives and now a new emerging threat of synthetic opioids. These compounds were mostly developed by pharmaceutical companies during drug discovery. The new psychoactive substances are not routinely covered in drug screening and may go undetected. Recently fentanyl analogous, AH- 7921, MT-45 and now U-47700 have been encountered in clinical and forensic casework. U-47700 is gaining popularity on drug user forms as a legal alternative to heroin. It is a μ-receptor agonist that is part of the trans-1-2-diamine opioid analgesic drug class developed by The Upjohn Company in an attempt to develop a non-addicting analgesic. A LC-MS-MS method was developed and validated to detect and quantify U-47700. Additional analysis was conducted with an LC-QToF to identify the presence of the parent drug and metabolites. A total of four cases have been evaluated by the LC-MS-MS methodology which has an analytical range of 1-1,250 ng/mL and limit of detection of 1 ng/mL. The concentration of U-47700 in urine specimens ranged from below the limit of quantification to 224 ng/mL. The ToF analysis detected the presence of suspected phase I demethylated metabolites that may assist future analysis of this compound. The prevalence of designer opioids in casework highlights the importance of analysis for new psychoactive substances. Traditional opiates/opioids were not detected in the presented cases, but the available case histories revealed an opioid toxidrome. These findings suggest that U-47700 drug may cause significant morbidity and mortality within the United States as an emerging drug threat.

Original languageEnglish (US)
Pages (from-to)173-180
Number of pages8
JournalJournal of Analytical Toxicology
Volume41
Issue number3
DOIs
StatePublished - Apr 1 2017

Fingerprint

Metabolites
urine
Opioid Analgesics
drug
Urine
Pharmaceutical Preparations
Drug products
Industry
Screening
Analgesics
Opiate Alkaloids
Derivatives
Preclinical Drug Evaluations
Diamines
Cannabinoids
Heroin
Street Drugs
Fentanyl
Drug Discovery
metabolite

ASJC Scopus subject areas

  • Analytical Chemistry
  • Environmental Chemistry
  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Chemical Health and Safety

Cite this

Fleming, S. W., Cooley, J. C., Johnson, L., Clinton Frazee, C., Domanski, K., Kleinschmidt, K., & Garg, U. (2017). Analysis of U-47700, a novel synthetic opioid, in human urine by LC-MS-MS and LC-QToF. Journal of Analytical Toxicology, 41(3), 173-180. https://doi.org/10.1093/jat/bkw131

Analysis of U-47700, a novel synthetic opioid, in human urine by LC-MS-MS and LC-QToF. / Fleming, Steven W.; Cooley, Justin C.; Johnson, Leonard; Clinton Frazee, C.; Domanski, Kristina; Kleinschmidt, Kurt; Garg, Uttam.

In: Journal of Analytical Toxicology, Vol. 41, No. 3, 01.04.2017, p. 173-180.

Research output: Contribution to journalArticle

Fleming, SW, Cooley, JC, Johnson, L, Clinton Frazee, C, Domanski, K, Kleinschmidt, K & Garg, U 2017, 'Analysis of U-47700, a novel synthetic opioid, in human urine by LC-MS-MS and LC-QToF', Journal of Analytical Toxicology, vol. 41, no. 3, pp. 173-180. https://doi.org/10.1093/jat/bkw131
Fleming, Steven W. ; Cooley, Justin C. ; Johnson, Leonard ; Clinton Frazee, C. ; Domanski, Kristina ; Kleinschmidt, Kurt ; Garg, Uttam. / Analysis of U-47700, a novel synthetic opioid, in human urine by LC-MS-MS and LC-QToF. In: Journal of Analytical Toxicology. 2017 ; Vol. 41, No. 3. pp. 173-180.
@article{605356a11744482bba96205b41cfd903,
title = "Analysis of U-47700, a novel synthetic opioid, in human urine by LC-MS-MS and LC-QToF",
abstract = "The illicit drug market has rapidly evolved from synthetic cannabinoids to cathinone derivatives and now a new emerging threat of synthetic opioids. These compounds were mostly developed by pharmaceutical companies during drug discovery. The new psychoactive substances are not routinely covered in drug screening and may go undetected. Recently fentanyl analogous, AH- 7921, MT-45 and now U-47700 have been encountered in clinical and forensic casework. U-47700 is gaining popularity on drug user forms as a legal alternative to heroin. It is a μ-receptor agonist that is part of the trans-1-2-diamine opioid analgesic drug class developed by The Upjohn Company in an attempt to develop a non-addicting analgesic. A LC-MS-MS method was developed and validated to detect and quantify U-47700. Additional analysis was conducted with an LC-QToF to identify the presence of the parent drug and metabolites. A total of four cases have been evaluated by the LC-MS-MS methodology which has an analytical range of 1-1,250 ng/mL and limit of detection of 1 ng/mL. The concentration of U-47700 in urine specimens ranged from below the limit of quantification to 224 ng/mL. The ToF analysis detected the presence of suspected phase I demethylated metabolites that may assist future analysis of this compound. The prevalence of designer opioids in casework highlights the importance of analysis for new psychoactive substances. Traditional opiates/opioids were not detected in the presented cases, but the available case histories revealed an opioid toxidrome. These findings suggest that U-47700 drug may cause significant morbidity and mortality within the United States as an emerging drug threat.",
author = "Fleming, {Steven W.} and Cooley, {Justin C.} and Leonard Johnson and {Clinton Frazee}, C. and Kristina Domanski and Kurt Kleinschmidt and Uttam Garg",
year = "2017",
month = "4",
day = "1",
doi = "10.1093/jat/bkw131",
language = "English (US)",
volume = "41",
pages = "173--180",
journal = "Journal of Analytical Toxicology",
issn = "0146-4760",
publisher = "Preston Publications",
number = "3",

}

TY - JOUR

T1 - Analysis of U-47700, a novel synthetic opioid, in human urine by LC-MS-MS and LC-QToF

AU - Fleming, Steven W.

AU - Cooley, Justin C.

AU - Johnson, Leonard

AU - Clinton Frazee, C.

AU - Domanski, Kristina

AU - Kleinschmidt, Kurt

AU - Garg, Uttam

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The illicit drug market has rapidly evolved from synthetic cannabinoids to cathinone derivatives and now a new emerging threat of synthetic opioids. These compounds were mostly developed by pharmaceutical companies during drug discovery. The new psychoactive substances are not routinely covered in drug screening and may go undetected. Recently fentanyl analogous, AH- 7921, MT-45 and now U-47700 have been encountered in clinical and forensic casework. U-47700 is gaining popularity on drug user forms as a legal alternative to heroin. It is a μ-receptor agonist that is part of the trans-1-2-diamine opioid analgesic drug class developed by The Upjohn Company in an attempt to develop a non-addicting analgesic. A LC-MS-MS method was developed and validated to detect and quantify U-47700. Additional analysis was conducted with an LC-QToF to identify the presence of the parent drug and metabolites. A total of four cases have been evaluated by the LC-MS-MS methodology which has an analytical range of 1-1,250 ng/mL and limit of detection of 1 ng/mL. The concentration of U-47700 in urine specimens ranged from below the limit of quantification to 224 ng/mL. The ToF analysis detected the presence of suspected phase I demethylated metabolites that may assist future analysis of this compound. The prevalence of designer opioids in casework highlights the importance of analysis for new psychoactive substances. Traditional opiates/opioids were not detected in the presented cases, but the available case histories revealed an opioid toxidrome. These findings suggest that U-47700 drug may cause significant morbidity and mortality within the United States as an emerging drug threat.

AB - The illicit drug market has rapidly evolved from synthetic cannabinoids to cathinone derivatives and now a new emerging threat of synthetic opioids. These compounds were mostly developed by pharmaceutical companies during drug discovery. The new psychoactive substances are not routinely covered in drug screening and may go undetected. Recently fentanyl analogous, AH- 7921, MT-45 and now U-47700 have been encountered in clinical and forensic casework. U-47700 is gaining popularity on drug user forms as a legal alternative to heroin. It is a μ-receptor agonist that is part of the trans-1-2-diamine opioid analgesic drug class developed by The Upjohn Company in an attempt to develop a non-addicting analgesic. A LC-MS-MS method was developed and validated to detect and quantify U-47700. Additional analysis was conducted with an LC-QToF to identify the presence of the parent drug and metabolites. A total of four cases have been evaluated by the LC-MS-MS methodology which has an analytical range of 1-1,250 ng/mL and limit of detection of 1 ng/mL. The concentration of U-47700 in urine specimens ranged from below the limit of quantification to 224 ng/mL. The ToF analysis detected the presence of suspected phase I demethylated metabolites that may assist future analysis of this compound. The prevalence of designer opioids in casework highlights the importance of analysis for new psychoactive substances. Traditional opiates/opioids were not detected in the presented cases, but the available case histories revealed an opioid toxidrome. These findings suggest that U-47700 drug may cause significant morbidity and mortality within the United States as an emerging drug threat.

UR - http://www.scopus.com/inward/record.url?scp=85018961559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018961559&partnerID=8YFLogxK

U2 - 10.1093/jat/bkw131

DO - 10.1093/jat/bkw131

M3 - Article

C2 - 28035035

AN - SCOPUS:85018961559

VL - 41

SP - 173

EP - 180

JO - Journal of Analytical Toxicology

JF - Journal of Analytical Toxicology

SN - 0146-4760

IS - 3

ER -